Related Experiment Video
Updated: Apr 23, 2026
06:02
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
7.0K
Thrombotic Thrombocytopenic Purpura in a Patient With Triple-Negative Breast Cancer Treated With PD-L1 Inhibition and
Jason Ke1, Albert C Chong1,2, Robert Hsu1
1University of Southern California Keck School of Medicine Los Angeles California USA.
Clinical Case Reports
|April 22, 2026
Abstract:
Thrombocytopenic purpura (TTP) is a hematologic emergency that may occur with PD-L1 immunotherapy. New or worsening anemia and thrombocytopenia in patients started on PD-L1 inhibitors should raise suspicion for TTP and prompt workup for thrombotic microangiopathy.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
02:57Targeted Cancer Therapies
6.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
6.9K